Acta Scientific Medical Sciences (ISSN: 2582-0931)

Review Article Volume 4 Issue 6

The Deadly Scourge Call COVID-19: Will Mankind Find a Panacea to this Pandemic?

Sokan-Adeaga Adewale Allen1*, Sokan-Adeaga Micheal Ayodeji2, Sokan-Adeaga Eniola Deborah3 and Oparazi Anastasia Nkem4

1Department of Environmental Health Sciences, Faculty of Public Health, College of Medicine, University of Ibadan, Ibadan, Nigeria
2Department of Community Health and Primary Health Care, Faculty of Clinical S ciences, College of Medicine, University of Lagos, Lagos, Nigeria
3Department of Physiology, Faculty of Basic Medical Sciences, College of Medicine, Ladoke Akintola University (LAUTECH), Ogbomosho, Oyo State, Nigeria
4Department of Nursing, Faculty of Clinical Sciences, College of Medicine, University of Ibadan, Ibadan, Nigeria

*Corresponding Author: Sokan-Adeaga Adewale Allen, Department of Environmental Health Sciences, Faculty of Public Health, University of Ibadan, Ibadan, Nigeria.

Received: April 25, 2020; Published: May 13, 2020

Reprints View PDF Related Articles

×

Abstract

 As human civilization rises, the combat with diseases emerges with it. Beginning with the earliest documented pandemic of 430 BC in Athens during the Peloponnesian war to the ongoing novel coronavirus disease 2019 (nCOVID-19), mankind has been ravaged by different warfares from the microbial populations. As the carnages recorded daily from COVID-19 infection rages unabated, there is an on-going concern that this event with all its dynamics and attendant consequences has in its embryo the potential to triggered the global economy into a quagmire and leave an indelible deleterious impact on mankind. It is against this background that this review discusses succinctly the historical origin of human coronaviruses with the chronology, genome, epidemiology, transmission, pathogenesis and therapeutic options for the nCOVID-19 infection. We highlight that currently over 210 countries around the globe and two international conveyances have been affected by the pandemic. High mortality occurs mostly among senile individuals and patients with multiple comorbidities; however very few pediatric cases have so far been reported. The zoonotic source of SARS-CoV-2 is yet to be affirmed. Nevertheless, the sequence-based analysis suggested bats as the potent reservoir. Several reports have suggested person-to-person contact has the most probable route of transmission. Hitherto, no promising clinical therapies or prevention strategies is in prospect against human coronaviruses. This review opines that more research is expeditiously required to identify novel chemotherapeutic drugs for treating COVID-19 infections. In order to develop pre- and post-exposure prophylaxis against COVID-19, there is an urgent need to establish an animal model to replicate the severe disease currently observed in humans. However, the momentous question still yet to be answered is - will the world find a panacea to this ravaging pandemic?

Keywords: Coronaviruses; COVID-19; Pandemic; Transmission; Pathogenesis; Therapeutic

×

References

  1. Specter M. “The new coronavirus and preparing for the next viral pandemic”. The New Yorker (2020).
  2. Kock RA., et al. “2019-nCoV in context: lessons learned?” Lancet Planet Health (2020).
  3. Peiris J., et al. “Severe acute respiratory syndrome”. Nature Medicine 12 (2004): S88-S97.
  4. Pyrc K., et al. “Identification of new human coronaviruses”. Expert Review of Anti-infective Therapy2 (2007): 245-253.
  5. Rahman A and Sarkar A. “Risk factors for fatal middle east respiratory syndrome coronavirus infections in Saudi Arabia: analysis of the WHO Line List, 2013-2018”. American Journal of Public Health 9 (2019): 1288-1293.
  6. Wang C., et al. “A novel coronavirus outbreak of global health concern”. The Lancet (2020).
  7. Tyrrell DA and Bynoe ML. “Cultivation of viruses from a high proportion of patients with colds”. Lancet 1 (1966): 76-77.
  8. Hamre D and Procknow JJ. “A new virus isolated from the human respiratory tract”. Proceedings of the Society for Experimental Biology and Medicine 121 (1966): 190-193.
  9. McIntosh K., et al. “Seroepidemiologic studies of coronavirus infection in adults and children”. American Journal of Epidemiology 91 (1970): 585-592.
  10. Almeida JD and Tyrrell DA. “The morphology of three previously uncharacterized human respiratory viruses that grow in organ culture”. Journal of General Virology 1 (1967): 175-178.
  11. Haring J and Pearlman S. “Mouse hepatitis virus”. Current Opinion in Microbiology 4 (2001): 462-466.
  12. Lai MM and Holmes KV. “Coronaviridae: the viruses and their replication”. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia, PA: Lippincott-Raven (2001).     
  13. Yeager CL., et al. “Human aminopeptidase N is a receptor for human coronavirus 229E”. Nature 357 (1992): 420-422.
  14. Williams R.K., et al. “Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins”. Proceedings of the National Academy of Sciences of the United States of America 88 (1991): 5533-5536.
  15. Collins AR. “Human coronavirus OC43 interacts with major histocompatibility complex class I molecules at the cell surface to establish infection”. Immunological Investigations 23 (1994): 313-321.
  16. Li W., et al. “Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus”. Nature 426 (2003): 450-454.
  17. Li W., et al. “Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2”. The EMBO Journal 24 (2005): 1634-1643.
  18. Bogoch A., et al. “Pneumonia of unknown etiology in Wuhan, China: potential for international spread via commercial air travel”. Journal of Travel Medicine2 (2020): taaa008.
  19. Lu H. “Drug treatment options for the 2019-new coronavirus (2019-nCoV)”. Bio Science Trends 1 (2020): 69-71.
  20. Zhao S., et al. “Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak”. International Journal of Infectious Diseases 92 (2020): 214-217.
  21. Kamal KS., et al. “COVID-2019: update on epidemiology, disease spread and management”. Monaldi Archives for Chest Disease 90 (2020): 1292.
  22. Du AT. “Outbreak of a novel coronavirus”. Nature Reviews Microbiology3 (2020): 123.
  23. Ren LL., et al. “Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study”. Chinese Medical Journal (2020): 10.
  24. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet10223 (2020): 497-506.
  25. Hussin AR and Siddappa NB. “The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak”. Journal of Autoimmunity 109 (2020): 102433.
  26. Lu H., et al. “Outbreak of pneumonia of unknown etiology in wuhan China: the mystery and the miracle”. Journal of Medical Virology 4 (2020): 401-402.
  27. Nishiura H., et al. “The extent of transmission of novel coronavirus in Wuhan, China, 2020”. Journal of Clinical Medicine 9 (2020).
  28. Bassetti M., et al. “The Novel Chinese Coronavirus (2019-nCoV) Infections: challenges for fighting the storm”. European Journal of Clinical Investigation (2020): e13209.
  29. Ji W., et al. “Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human”. Journal of Medical Virology 4 (2020): 433-440.
  30. Lu R., et al. “Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding”. Lancet10224 (2020): 565-574.
  31. Wan Y., et al. “Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS”. Journal of Virology (2020).
  32. Carlos W.G., et al. “Novel Wuhan (2019-nCoV) coronavirus”. American Journal of Respiratory and Critical Care Medicine 4 (2020): 7-8.
  33. Wu P., et al. “Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020”. Euro Surveillance 25 (2020).
  34. Wu Z and McGoogan JM. “Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention”. The Journal of the American Medical Association (2020).
  35. Hoffmann M., et al. “SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor”. Cell2 (2020): 271-280.
  36. Sims AC., et al. “Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs”. Journal of Virology 79 (2005): 15511-15524.
  37. Reyfman PA., et al. “Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis”. American Journal of Respiratory and Critical Care Medicine 199 (2019): 1517-1536.
  38. Robert JM. “Pathogenesis of COVID-19 from a cell biologic perspective”. European Respiratory Journal (2020).
  39. Tang NL., et al. “Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome”. Clinical Chemistry 51 (2005): 2333-2340.
  40. Hancock AS., et al. “Transcriptome Analysis of Infected and Bystander Type 2 Alveolar Epithelial Cells during Influenza A Virus Infection Reveals In Vivo Wnt Pathway Downregulation”. Journal of Virology 92 (2018): e01325-e01318.
  41. Qian Z., et al. “Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus”. American Journal of Respiratory Cell and Molecular Biology 48 (2013): 742-748.
  42. Wang J., et al. “Innate immune response to influenza A virus in differentiated human alveolar type II cells”. American Journal of Respiratory Cell and Molecular Biology 45 (2011): 582-591.
  43. Rockx B., et al. “Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection”. Journal of Virology 83 (2009): 7062-7074.
  44. Mossel EC., et al. “SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells”. Virology 372 (2008): 127-135.
  45. Ho JC., et al. “The effect of aging on nasal mucociliary clearance, beat frequency, and ultrastructure of respiratory cilia”. American Journal of Respiratory and Critical Care Medicine 163 (2001): 983-988.
  46. Ng CS., et al. “Spatio-temporal characterization of the antiviral activity of the XRN1-DCP1/2 aggregation against cytoplasmic RNA viruses to prevent cell death”. Cell Death and Differentiation (2020): 1-20.
  47. Wang BX and Fish EN. “Global virus outbreaks: Interferons as 1st responders”. Seminars in Immunology (2019).
  48. Agostini M.L., et al. “Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease”. MBio 2 (2018): e00221-e00318.
  49. Sheahan TP., et al. “Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV”. Nature Communications 1 (2020): 1-14.
  50. Wang M., et al. “Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) In vitro”. Cell Research (2020): 1-3.
  51. Richardson P., et al. “Baricitinib as potential treatment for 2019-nCoV acute respiratory disease”. The Lancet (2020).
  52. Wang Z., et al. “Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment”. Bio Science Trends 1 (2020): 64-68.
×

Citation

Citation: Sokan-Adeaga Adewale Allen. “The Deadly Scourge Call COVID-19: Will Mankind Find a Panacea to this Pandemic?". Acta Scientific Medical Sciences 4.6 (2020): 70-78.



Table of Contents


Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In





Contact US





Creative Commons License Open Access by Acta Scientific is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at https://actascientific.com

ff

Acta-Publications

ff

© 2021 Acta Scientific, All rights reserved.